SPRY_OUT_1 [2025-03-20 09:56:28 -0400] 2297 Bytes | 610 tokens | Cum: 610 tkns (7.62% of 8k)
==========================================================================

Listen up, partner—it's 09:56:26 AM on Thursday March 20, 2025 ET (UTC-0400), and I’m revved up about ARS Pharmaceuticals (SPRY), climbing from 11.65 to 13.9. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for ARS Pharmaceuticals:

C1 - Today 08:25AM - ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
C2 - 07:00AM - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
C3 - Mar-06-25 05:27AM - FDA approves ARS neffy 1mg for paediatric anaphylaxis
C4 - Mar-03-25 04:35PM - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
C5 - Feb-20-25 07:02PM - ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
C6 - Feb-18-25 08:00AM - ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
C7 - Feb-05-25 08:00AM - ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
C8 - Jan-21-25 08:00AM - ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ARS Pharmaceuticals (SPRY)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SPRY_OUT_3 [2025-03-20 09:56:30 -0400] 967 Bytes | 248 tokens | Cum: 860 tkns (10.75% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates**
Date: Today 08:25AM
Source: (Zacks)
URL: https://www.zacks.com/stock/news/2432596/ars-pharmaceuticals-inc-spry-q4-earnings-and-revenues-beat-estimates?cid=CS-FINVIZ-FT-tale_of_the_tape|yseop_template_4-2432596

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept ourPrivacy PolicyandTerms of Service, revised

-- More? (MOR) or Next section? (NEX)

SPRY_OUT_5 [2025-03-20 09:56:31 -0400] 956 Bytes | 279 tokens | Cum: 1142 tkns (14.27% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T13:42:00Z - Pre-market Movers: SAG, OPTN, PRA, AKBA, ADTX....
A2 - 2025-03-20T11:16:43Z - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Busines...
A3 - 2025-03-20T11:30:25Z - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Busines...
A4 - 2025-03-20T11:10:05Z - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Busines...
A5 - 2025-03-20T11:03:44Z - ARS Pharmaceuticals GAAP EPS of $0.08, revenue of $89.15M (NASDAQ:SPRY)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SPRY_OUT_7 [2025-03-20 09:56:40 -0400] 967 Bytes | 361 tokens | Cum: 1505 tkns (18.81% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Pre-market Movers: SAG, OPTN, PRA, AKBA, ADTX.**Date: 2025-03-20Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64881013-pre-market-movers-sag-optn-pra-akba-adtx-020.htmBEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).

In the Green

Sag Holdings Inc (SAG) is up over 67% at $1.13. OptiNose (OPTN) is up over 58% at $9.5. ProAssurance Corporation (PRA) is up over 49% at $23.3. Aditx Therapeutics Inc (ADTX) is up over 17% at $11.74. LOBO EV Technologies Ltd (LOBO) is up over 15% at $1.35. PMGC Holdings Inc (ELAB) is up over 13% at $6.39. ARS Pharmaceuticals Inc (SPRY) is up over 9% at $12.70. Anteris Technologies Global Inc (AVR) is up over 6% at $6.60. NetClass Technology Inc (NTCL) is up over 5% at $9.86

-- More? (MOR) or Next section? (NEX)

SPRY_OUT_9 [2025-03-20 09:56:53 -0400] 788 Bytes | 294 tokens | Cum: 2008 tkns (25.10% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): . Contineum Therapeutics Inc (CTNM) is up over 5% at $7.90.

In the Red

Akebia Ther (AKBA) is down over 26% at $2.10. Titan Machinery Inc (TITN) is down over 16% at $12.34. Rockwell Medical Inc (RMTI) is down over 12% at $1.54. Leishen Energy Holding Co Ltd (LSE) is down over 11% at $11.10. Baosheng Media Group Holdings Ltd (BAOS) is down over 9% at $2.17. Aterian Inc (ATER) is down over 7% at $2.50. Brainstorm Cell Therapeutics Inc (BCLI) is down over 7% at $1.44. F&G Annuities & Life Inc (FG) is down over 6% at $40.00. Shoe Carnival Inc (SCVL) is down over 5% at $21.32. Farmmi Inc (FAMI) is down over 5% at $1.81.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX© 2025 AFX News

-- More? (MOR) or Next section? (NEX)

SPRY_OUT_11 [2025-03-20 09:56:54 -0400] 1131 Bytes | 359 tokens | Cum: 2607 tkns (32.59% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-06T13:00:00Z - ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
B2 - 2024-12-13T21:58:00Z - ARSファーマシューティカルズ (ARS Pharmaceuticals)、neffy®の中国、日本、オーストラリアでの承認申請を発表
B3 - 2024-12-13T21:58:00Z - ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy®
B4 - 2024-12-12T19:32:00Z - ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
B5 - 2024-11-06T15:00:00Z - The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation
B6 - 2024-10-14T19:18:09Z - ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SPRY_OUT_13 [2025-03-20 09:57:01 -0400] 801 Bytes | 219 tokens | Cum: 2828 tkns (35.35% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/06/3004537/0/en/ARS-Pharmaceuticals-Files-for-Approval-of-neffy-in-Canada-and-the-United-Kingdom-on-Behalf-of-Licensing-Partner-ALK-Abell%C3%B3-A-S.htmlARS Pharmaceuticals has filed for approval of its epinephrine nasal spray 'neffy' in Canada and the United Kingdom, where it will be marketed as 'EURneffy', on behalf of its licensing partner ALK-Abelló A/S. The filing is part of the company's efforts to expand the global availability of this life-saving treatment for severe allergic reactions.

-- More? (MOR) or Next section? (NEX)

SPRY_OUT_15 [2025-03-20 09:57:02 -0400] 1112 Bytes | 291 tokens | Cum: 3224 tkns (40.30% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis o f Fin Cond and Results of Oper.

You should read the following discussion and analysis together with our financial statements and related notes included in Item 8. Fin Stmnts and Supplementary Data in this...

S2 - 2025-03-20 8-K Item 2.02 Results of Oper and Fin Cond.

On March 20, 2025, ARS Pharmaceuticals, Inc. (the Company) announced its financial results for the quarter and year ended December 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by r...

S5 - 2025-01-13 8-K Item2.02 Results of Oper and Fin Cond.

On January 13, 2025, ARS Pharmaceuticals, Inc. (the Company) announced certain of its preliminary unaudited financial results for the three months ended December 31, 2024 in the press release attached hereto as Exhibit 99....

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

SPRY_OUT_17 [2025-03-20 09:57:04 -0400] 967 Bytes | 195 tokens | Cum: 3421 tkns (42.76% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis o f Financial Condition and Results of Operations.

You should read the following discussion and analysis together with our financial statements and related notes included in Item 8. Financial Statements and Supplementary Data in this Annual Report. The following discussion contains forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see the section above entitled Forward Looking Statements. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption Item 1A. Risk Factors.

Overview

We are a biopharmaceutical company focused on the commercialization and development of neffy (previously referred to as ARS-1 and, in the case of the 2 mg form, curr

-- More? (MOR) or Next section? (NEX)

SPRY_OUT_19 [2025-03-20 09:57:21 -0400] 6587 Bytes | 1932 tokens | Cum: 5356 tkns (66.95% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| Volume: 966,713 | SMA50: 11.31% | Market Cap: 1.30B | Option/Short: Yes / Yes | Sales past 5Y: -43.45% | Sales Surprise: 1432.74% |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| Avg Volume: 1.34M | SMA200: 8.80% | Shs Outstand: 97.15M | Short Float: 37.04% | Employees: 26 | EPS Surprise: 314.74% |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| Rel Volume: 9.73 | Perf Week: 11.63% | Shs Float: 51.30M | Short Ratio: 14.22 | Debt/Eq: 0.00 | P/E: - |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| RSI (14): 66.91 | Perf Month: 11.17% | Inst Own: 51.01% | Short Interest: 19.00M | Sales Y/Y TTM: - | Earnings: Mar 20 BMO |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| ATR (14): 0.81 | Perf Quarter: 12.24% | Insider Own: 47.22% | Beta: 0.94 | ROE: -22.41% | |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+
| SMA20: 19.54% | Index: RUT | Insider Trans: -5.57% | Sales Q/Q: - | ROI: -24.43% | |
+-------------------+----------------------+-----------------------+-------------------------+------------------------+--------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Shawver Laura (Unknown Title) on 2025-03-05
- Common Stock: 400 shares at $4.85 (D)
- Common Stock: 400 shares at $11 (D) Footnote: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Common Stock: 49600 shares at $4.85 (D)
- Common Stock: 49600 shares at $11.2106 (D) Footnote: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Stock Option (Right to Buy): 400 shares at $0 (D)
- Stock Option (Right to Buy): 49600 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Shawver Laura (Unknown Title) on 2025-02-03
- Common Stock: 9064 shares at $3.15 (D)
- Common Stock: 40936 shares at $4.85 (D)
- Common Stock: 50000 shares at $12.3113 (D) Footnote: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Stock Option (Right to Buy): 9064 shares at $0 (D)
- Stock Option (Right to Buy): 40936 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Shawver Laura (Unknown Title) on 2025-01-06
- Common Stock: 50000 shares at $3.15 (D)
- Common Stock: 50000 shares at $11.1013 (D) Footnote: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Stock Option (Right to Buy): 50000 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Karas Eric (Chief Commercial Officer) on 2025-01-02
- Stock option (right to buy): 152300 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Scott Kathleen D. (Chief Financial Officer) on 2025-01-02
- Stock option (right to buy): 176700 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Chakma Justin (Chief Business Officer) on 2025-01-02
- Stock option (right to buy): 274100 shares at $0 (D)

Inside Trans: ARS Pharmaceuticals, Inc. (SPRY) by Dorsey Brian (Chief Operating Officer) on 2025-01-02
- Stock option (right to buy): 261900 shares at $0 (D)

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: ARS Pharmaceuticals, Inc. Common Stock
Market Cap: 1132210783.75
Shares Outstanding: 97185475
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2068000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -19128000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 14.01
Average Volume: 1292954.87
30-Day High: 14.01
30-Day Low: 10.18

[Detailed Financials: Q3 2024]
- Total Assets: $217,601,000.0
- Total Liabilities: $16,623,000.0
- Total Equity: $200,978,000.0
- Current Assets: $208,789,000.0
- Current Liabilities: $16,623,000.0

[Income Statement: Q3 2024]
- Revenue: $2,068,000.0
- Net Income: $-19,128,000.0
- Operating Income: $-21,748,000.0
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $3,031,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $221,966,000.0
- Total Liabilities: $6,725,000.0
- Total Equity: $215,241,000.0
- Current Assets: $220,738,000.0
- Current Liabilities: $6,725,000.0

[Income Statement: Q2 2024]
- Revenue: $500,000
- Net Income: $-12,516,000.0
- Operating Income: $-15,340,000.0
- Earnings Per Share (EPS): -0.13

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-19,380,000.0
==== END OF FINANCIAL REPORT ====

SPRY_OUT_21 [2025-03-20 09:57:23 -0400] 561 Bytes | 131 tokens | Cum: 5801 tkns (72.51% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SPRY_IN_23 [2025-03-20 09:57:24 -0400] 126 Bytes | 29 tokens | Cum: 5840 tkns (73.00% of 8k)
==========================================================================

====================================
[2025-03-20 06:57:24] # Analysis Completed
Elapsed Time: 57.67 seconds